Number observed with ≥3-point NRS improvement: 157 (Yes=82, No=75; missing n=32) and 165 (Yes=51, No=114; missing n=24) for KORSUVA and placebo, respectively. Counts were based on non-missing data.
Estimated percent and P-value used a logistic regression model with terms for treatment group, baseline Worst Itching Intensity numerical rating scale score, use of anti-itch medication during the week prior to randomization, and the presence of specific medical conditions. Missing values were imputed using multiple imputation under missing-at-random missing data assumption for interim patients and post-interim patients separately.
Adapted from the Product Monograph.¹